evipedia.ai
← Back

Low-Level Light Therapy for Health & Longevity

Evidence Review created on 11/04/2026 using AI4L / Opus 5.5

Also known as: Photobiomodulation, Photobiomodulation Therapy, PBM, PBMT, Low-Level Laser Therapy, LLLT, Low-Power Laser Therapy, Low-Power Laser Irradiation, Laser Biostimulation, Laser Phototherapy, Red Light Therapy, Near-Infrared Light Therapy, Cold Laser Therapy, Soft Laser Therapy, Low-Intensity Laser Therapy, LED Light Therapy

Motivation

Low-level light therapy shines red and near-infrared light onto the skin, scalp, eyes, or head at strengths too weak to heat or cut tissue. The light is thought to be absorbed inside the energy-producing parts of cells, shifting how they make energy and respond to stress. It draws interest because it is painless, drug-free, and now sold for home use as panels, masks, caps, and helmets.

The approach began in the late 1960s, when a Hungarian surgeon noticed unexpected effects of a weak laser on mice. Since then it has been tested in many clinical trials, mostly for pain and tissue repair, and more recently for age-related changes in the eye. Device makers, clinics, and podcasts now promote it widely for general wellness.

This review examines what the human evidence shows for and against low-level light therapy in health-focused adults: which uses rest on controlled trials, which rest on animal or early data, what the known and possible harms are, and how the protocols used in studies are structured.

Benefits - Risks - Protocol - Conclusion

In-depth discussions of red and near-infrared light therapy from longevity-focused experts, plus one mechanistic review.

Content from Chris Kresser and Lifespan.io is not included: chriskresser.com offers near-infrared sauna articles and only a passing guest mention of photobiomodulation for preventing mouth sores during childhood cancer treatment (Revolution Health Radio episode), and his only direct light-therapy comment is a reader Q&A answer, an excluded format (Kresser Institute Q&A); Lifespan.io’s only coverage is a news summary of a single mouse study (Lifespan.io news summary) rather than an overview.

Grokipedia

Low-level laser therapy

AI-generated encyclopedia entry covering low-level laser therapy and photobiomodulation terminology, history since 1967, proposed mechanisms, indications, United States regulatory status, and contraindications; useful as orientation, not as a primary source.

Examine

Red Light Therapy

Independent evidence summary grading red and near-infrared light therapy by outcome, identifying hair loss, joint pain, and childhood nearsightedness as the best-supported uses, with linked study summaries.

ConsumerLab

Does red and near infrared light therapy reduce pain, improve skin or cognition, or have other benefits? Is it safe?

Independent review of device evidence for pain, skin, hair, cognition, and nerve pain, with eye-safety and darker-skin cautions and reports of false manufacturer claims; full text requires membership.

Systematic Reviews

Systematic reviews and meta-analyses, mostly of randomized controlled trials (RCTs, studies that assign treatment by chance), covering the broadest benefit claims and the principal safety concern.

Mechanism of Action

Low-level light therapy uses red (about 600–700 nm; nm = nanometers, the unit of wavelength) and near-infrared (about 780–1,000 nm) light at intensities too low to heat tissue meaningfully. The leading model holds that cytochrome c oxidase (the final enzyme of the mitochondrial energy chain) absorbs these photons, displacing inhibitory nitric oxide (NO, a signaling gas) and raising production of ATP (adenosine triphosphate, the cell’s energy currency) (a review, Hamblin 2017). A brief rise in reactive oxygen species (ROS, oxygen-derived signaling molecules) then activates NF-κB (a master switch for inflammatory and repair genes) and related transcription factors, shifting cells toward repair, lower inflammation, and new blood-vessel growth. Released NO also widens local blood vessels.

  • Dose dependence: Effects follow a biphasic dose curve: too little light does nothing, a moderate dose stimulates, and too much inhibits (a review, Huang 2009).
  • Competing explanations: Quirk and Whelan argue that a direct light effect on cytochrome c oxidase has never been reliably demonstrated and that light-triggered NO release may be the core mechanism (Quirk 2020). The Jeffery group proposes instead that long wavelengths lower the viscosity of water around ATP-producing enzymes (Shinhmar 2021).
  • Penetration: Red light acts mainly in skin and the retina; near-infrared penetrates deeper into muscle, joints, and the outer brain.
  • Skeptical view: Warmth and visible glow make blinding difficult, so sham-controlled trials (comparisons with an inactive imitation device) are essential to separate light effects from placebo responses.

Historical Context & Evolution

In 1967 Hungarian surgeon Endre Mester exposed shaved mice to a low-power ruby laser and observed faster hair regrowth rather than harm (Mester 1968). His group went on to apply low-power lasers to chronic wounds, establishing the original intended uses: wound healing and pain relief in physical therapy.

  • Light-emitting diodes: In the 1990s, NASA-funded light-emitting diode arrays built for plant-growth experiments were tested on wound healing (Whelan 2001), making large-area, low-cost devices possible.
  • Inconsistent results: For decades, trials disagreed. A later review attributed many negative trials to too little or too much light (Huang 2009). In knee osteoarthritis, a 2015 meta-analysis found no benefit (Huang 2015), whereas a 2019 dose-stratified analysis found benefit at recommended doses and noted that major guidelines do not recommend it (Stausholm 2019). The question remains open rather than settled in either direction.
  • New name: The field adopted the term photobiomodulation to cover lasers and LEDs (light-emitting diodes) alike.
  • Health optimization: Interest from longevity-focused adults grew from mitochondrial theories of aging, fruit-fly lifespan data (Begum 2015), human vision studies (Shinhmar 2020), US Food and Drug Administration (FDA)-cleared home hair devices (counted in a systematic review, Lueangarun 2021), and the 2024 FDA authorization of a device for dry macular degeneration (FDA De Novo DEN230083).

Expected Benefits

High 🟩 🟩 🟩

Chronic Musculoskeletal and Nerve Pain ⚠️ Conflicted

Light over painful joints, tendons, or nerves reduces pain, probably by calming local inflammation and nerve excitability. Meta-analyses pooling trials from independent groups support this: Chow 2009 (neck pain, 16 RCTs), Stausholm 2019 (knee osteoarthritis, 22 RCTs), Yeh 2019 (fibromyalgia, a widespread chronic-pain disorder), and Lu 2023 (burning mouth syndrome, chronic oral burning pain); a dermatology-led consensus adds peripheral neuropathy (limb nerve damage) (Maghfour 2025). A smaller knee meta-analysis found no benefit (Huang 2015). The larger, dose-stratified analysis outweighs it, so benefit at recommended doses is the net reading.

Magnitude: Pain 14.2 mm lower than placebo on a 100 mm visual analogue scale (VAS, a 0–100 pain line) at end of therapy, 95% CI (confidence interval, the range likely to contain the true effect) 7.3 to 21.1, in knee osteoarthritis (Stausholm 2019); 19.4 mm (95% CI 9.7 to 29.2) in neck pain, a figure corrected after publication from the 19.9 mm in the original abstract (Chow 2009); fibromyalgia pain SMD (standardized mean difference, effect size in standard-deviation units) 1.18 (95% CI 0.82 to 1.54) (Yeh 2019); burning-mouth pain SMD −0.87 (95% CI −1.29 to −0.45) (Lu 2023).

Cognitive Function in Mild Cognitive Impairment and Dementia

Near-infrared light aimed through the skull (transcranial photobiomodulation) is thought to raise brain energy production and blood flow. Sham-controlled RCTs in mild cognitive impairment (a decline short of dementia) from independent groups in Brazil (de Oliveira 2024, 93 adults), Korea (Chun 2026, 80 adults), and Canada (Rashidi-Ranjbar 2026, 20 adults) each found better cognitive scores than sham. Trials are small and short (6–12 weeks); the Canadian trial included an employee of device maker Vielight. No trial yet shows slower progression to dementia.

Magnitude: Global cognition SMD 0.51 versus control (95% CI 0.16 to 0.86) across 11 RCTs (Gao 2023).

Prevention of Oral Mucositis During Cancer Treatment ⚠️ Conflicted

Oral mucositis (painful mouth ulceration from cancer treatment) is less frequent and severe with light applied inside the mouth. Oberoi 2014 pooled 18 RCTs; the Brazilian National Cancer Institute ran another (Antunes 2013). The MASCC/ISOO (Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology) guideline, some of whose members deliver this therapy, recommends specific protocols (Zadik 2019). A São Paulo phase III RCT found no reduction in severe mucositis (Gouvêa de Lima 2012). Net reading: the pooled trials outweigh it, so prevention is likely.

Magnitude: Severe mucositis risk ratio (RR, risk with light divided by risk without) 0.37 versus placebo or no therapy (95% CI 0.20 to 0.67) across 18 RCTs (Oberoi 2014).

Hair Regrowth in Pattern Hair Loss ⭕️ Not Central to Health & Longevity

Red light on the scalp is thought to prolong the growth phase of hair follicles in androgenetic alopecia (genetically driven male and female pattern hair loss). Double-blind sham-controlled RCTs from independent groups, Jimenez 2014 (University of Miami, sponsored by device maker Lexington International) and Kim 2013 (Seoul National University Bundang Hospital), were pooled by Liu 2019, and a systematic review counted dozens of FDA-cleared home devices (Lueangarun 2021). Industry sponsorship of most trials is a conflict of interest. The benefit concerns appearance rather than health or lifespan.

Magnitude: Hair density SMD 1.32 versus sham (95% CI 0.99 to 1.64) across 11 RCTs (Liu 2019); terminal hairs (thick, pigmented hairs) increased by 18.4–25.7 per cm² versus 1.6–9.4 per cm² with sham at 26 weeks (Jimenez 2014).

Reduced Waist and Body Circumference ⭕️ Not Central to Health & Longevity

Red laser light over the waist, hips, and thighs is proposed to make fat cells release stored fat, shrinking local girth. Controlled RCTs from US groups, Jackson 2009 (sham-controlled, co-authored by Erchonia, the device maker, a conflict of interest) and Caruso-Davis 2011 (Louisiana State University), found greater circumference loss, and a systematic review pooled three RCTs with 160 participants (Mustafa 2025). Follow-up is short, and Jackson 2009 reported partial regain after treatment ended. The benefit concerns body shape rather than health or lifespan.

Magnitude: Waist girth loss 2.15 cm greater than sham controls (inactive device) after 4 weeks of twice-weekly sessions (Caruso-Davis 2011); combined waist, hip, and thigh circumference fell 3.51 inches versus 0.68 inches with sham over 2 weeks, not compared between groups (Jackson 2009).

Healing of Diabetic Foot Ulcers

Light applied to chronic ulcers is thought to speed new tissue and blood-vessel formation. Three independent meta-analyses, by Li 2018 (7 RCTs), Zhou 2021 (12 RCTs), and Huang 2021 (13 RCTs), each found more complete healing and smaller ulcer area than control care, although Huang 2021 rated certainty very low. Trials are small and treatment settings vary widely. The finding concerns diabetic ulcer care, not healthy skin.

Magnitude: Complete healing RR 2.10 versus control (95% CI 1.56 to 2.83) across 13 RCTs (Huang 2021); ulcer area 30.9% smaller than control across 12 RCTs (Zhou 2021); complete healing odds ratio (OR, odds of healing with light relative to control) 6.72 (95% CI 1.99 to 22.64) (Li 2018).

Slower Nearsightedness Progression in Children ⭕️ Not Central to Health & Longevity

Repeated low-level red light (RLRL, brief twice-daily 650 nm exposures into the eye) slows axial elongation (lengthening of the eyeball, which drives nearsightedness) in children. Multicenter RCTs led by separate Chinese groups, Xu 2024 (Shanghai Eye Hospital) and Liu 2025 (Tianjin Medical University), support it; Xiong 2024 (Zhongshan Ophthalmic Center) shares Tianjin co-investigators. This benefit concerns childhood eye growth, not adult health or longevity, and it is the setting of the main retinal-injury case report (see Risks).

Magnitude: Axial length grew 0.33 mm less than control (95% CI 0.13 to 0.52) in a meta-analysis of four RCTs and one observational study (Amaral 2024); 0.29 mm less than orthokeratology (overnight reshaping contact lenses) alone over 12 months (95% CI 0.14 to 0.44) (Xiong 2024); −0.11 mm versus +0.32 mm with spectacles alone over 12 months, not compared between groups (Liu 2025).

Recovery From Bell’s Palsy

Randomized trials from independent groups in Egypt (Alayat 2014) and Turkey (Ordahan 2017) found better recovery from Bell’s palsy (sudden one-sided facial paralysis from facial-nerve inflammation) when laser was added to exercise. Lin 2024 reviewed 12 randomized trials (597 patients), pooling nine, and found improved facial-nerve grading, symmetry, and function compared with control care, and better severity scores than electrical stimulation, with no adverse effects reported. Most included trials were small.

Magnitude: House-Brackmann grade (a 1–6 facial-paralysis scale) 1.51 points better than control care (95% CI 0.59 to 2.43) (Lin 2024).

Dental Pain and Swelling ⚠️ Conflicted

Light on the jaw or teeth is thought to calm local inflammation and nerve sensitivity. Placebo-controlled meta-analyses from independent groups found less swelling after wisdom-tooth (third-molar) removal (Domah 2021; Lacerda-Santos 2023), less pain after orthodontic adjustments (Deana 2017), and less dentin hypersensitivity (tooth pain from exposed inner tooth layer) (Shan 2021). Post-surgical pain fell only in Lacerda-Santos 2023, not Domah 2021. Net reading: less swelling and tooth sensitivity are likely; post-surgical pain relief is uncertain.

Magnitude: Swelling SMD −0.61 versus placebo two days after third-molar surgery (95% CI −0.97 to −0.23) across 17 RCTs (Domah 2021); dentin hypersensitivity SMD 1.09 versus placebo immediately after treatment (95% CI 0.47 to 1.70) across 20 RCTs (Shan 2021).

Faster Healing of Recurrent Mouth Ulcers

Recurrent aphthous ulcers (canker sores, painful mouth ulcers that keep returning) are proposed to heal faster and hurt less when light speeds repair of the mouth lining. Sham-controlled RCTs from independent groups in Sweden (Albrektson 2014) and India (Aggarwal 2014) found less pain, and the Indian trial also found faster healing. A meta-analysis pooled 21 small RCTs with 810 patients, most at high risk of bias and five using brief low-power carbon dioxide laser rather than red or near-infrared light (Ma 2025).

Magnitude: Pain 3.47 points lower on a visual analogue scale one day after treatment than with sham or medication (95% CI 2.01 to 4.93), and healing 4.51 days faster (95% CI 1.99 to 7.02), in pooled RCTs (Ma 2025).

Faster Orthodontic Tooth Movement ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Light applied to the gums during orthodontic treatment is thought to speed the bone remodeling that shifts teeth. A Syrian meta-analysis found faster canine movement at 2–3 months, with low to very low certainty (Bakdach 2020, 25 RCTs); a Chinese one found pooled gains significant only at 1 month or with 780 nm light (Long 2015). A meta-analysis of nine trials found no consistent acceleration (Li 2021). This benefit concerns orthodontic treatment time, not health or lifespan. Net reading: a small acceleration is likely, but its clinical value is uncertain.

Magnitude: Upper canines moved 0.50 mm farther than non-irradiated control sides at month 2 and 0.49 mm farther at month 3 (Bakdach 2020).

Sleep Quality ⚠️ Conflicted

Light to the head or body is proposed to improve sleep through effects on brain energy metabolism. A meta-analysis pooled five small sham-controlled RCTs from separate groups (Chang, Chen, Ferrandez, Guu, Noda) in hemodialysis, insomnia, dry mouth, and depression; all were at high risk of bias, and one used violet rather than red light. A Beijing RCT in subjective cognitive decline (self-perceived memory decline) found no sleep-efficiency difference versus sham (Zhao 2022). Net reading: a modest improvement is likely, but its size is uncertain.

Magnitude: Pittsburgh Sleep Quality Index (PSQI, a 0–21 sleep questionnaire, lower is better) 1.25 points better than sham (95% CI 0.11 to 2.38) across five RCTs with 240 participants (Vital de Azevedo 2026).

Muscle Performance and Recovery ⚠️ Conflicted

Light applied to muscles before exercise is proposed to raise muscle energy supply and delay fatigue. Independent meta-analyses, Vanin 2018 (28 placebo-controlled trials, very low to moderate quality) and Li 2024 (34 RCTs), found gains in repetitions, time to exhaustion, and endurance in healthy people. Vanin’s senior author, Leal-Junior, leads trials co-sponsored by device maker Multi Radiance Medical (NCT02588768). Small independent crossover RCTs (participants receive both treatments in turn) found no effect (Flores 2023; Tsuk 2020). Net reading: a modest benefit is likely, but its size is uncertain.

Magnitude: Muscle endurance SMD 0.31 versus placebo (95% CI 0.11 to 0.51) across 34 RCTs of pre-exercise light, with no significant gain in physically active participants (Li 2024); positive results clustered at 20–60 J (joules, the delivered light energy) per small muscle group and 60–300 J per large muscle group (655–950 nm) (Vanin 2018).

Medium 🟩 🟩

Depressive Symptoms ⚠️ Conflicted

Light delivered to the head or body is proposed to improve brain energy metabolism and reduce inflammation. Seok 2026 pooled 18 trials in people with major depression or clinically significant symptoms and found a moderate reduction, with larger effects from systemic (body-wide rather than head-directed) delivery than from transcranial delivery. Sham-controlled RCTs of low-dose transcranial light found no antidepressant effect (Iosifescu 2022, 49 adults; Guu 2025, 48 adults). Net reading: a modest benefit is likely, but low-dose head devices may not deliver it.

Magnitude: Depressive symptoms Hedges’ g (a standardized effect size) −0.47 versus control (95% CI −0.73 to −0.22) across 18 trials (Seok 2026).

Skin Texture and Collagen

Red light is thought to stimulate fibroblasts (the skin cells that make collagen). In a trial of 136 adults, 30 twice-weekly sessions of 611–650 nm or 570–850 nm light improved blinded photograph ratings, skin roughness, and ultrasound-measured collagen density compared with untreated controls. Only the light groups were randomized; controls, mostly sponsor employees, were not randomized and received no sham device, and no independent group has replicated this. Light-device maker JK-Holding fully funded the trial and supplied the light sources, a conflict of interest.

Magnitude: Ultrasound collagen intensity score rose 5.75 points with 611–650 nm light versus a 0.26-point fall in untreated controls after 30 sessions; blinded raters judged wrinkles improved in 69% versus 4% of controls (Wunsch 2014).

Thyroid Function in Autoimmune Hypothyroidism

In a placebo-controlled RCT, 43 patients with autoimmune (Hashimoto’s) thyroiditis (immune destruction of the thyroid gland) taking levothyroxine (thyroid hormone replacement) received 10 sessions of 830 nm laser or placebo over the thyroid; after the drug was paused, the light group needed far less replacement and had lower thyroid peroxidase antibodies (markers of thyroid autoimmunity). All data come from one Brazilian group.

Magnitude: Levothyroxine needed 9 months later: 38.6 μg/day with light versus 106.9 μg/day with placebo (Höfling 2013).

Lower Post-Meal Blood Glucose

A 15-minute 670 nm exposure to the back, 45 minutes before an oral glucose tolerance test (OGTT, a 75 g glucose drink with timed blood-sugar checks), blunted the glucose rise in healthy adults, consistent with greater glucose use by light-stimulated mitochondria. The study randomized 30 people to light or no light. A Brazilian sham-controlled crossover trial in 10 adults with type 2 diabetes also found lower glucose after 830 nm light (Scontri 2023). Effects are acute and single-session, and longer-term glucose control was not measured.

Magnitude: Two-hour post-load glucose rise 27.7% lower than placebo; maximum glucose spike 7.5% lower (Powner 2024).

Prevention of Radiation Dermatitis During Radiotherapy ⚠️ Conflicted

Radiation dermatitis (skin inflammation and breakdown caused by radiotherapy) is proposed to be milder when light is applied to the irradiated skin from the start of treatment. Most randomized trials come from one Belgian group led by Robijns; Gobbo 2023 reviewed five trials in breast and head and neck cancer, four from that group, and pooled four. Aguiar 2021 rated the evidence very low certainty and found more mild dermatitis but less severe dermatitis with light. Net reading: fewer severe skin reactions are likely, but the evidence is thin.

Magnitude: Grade 2–3 rather than grade 0–1 dermatitis at the end of radiotherapy, OR 0.28 with light versus control (95% CI 0.15 to 0.53) across four RCTs (Gobbo 2023); grade 3 dermatitis RR 0.21 (95% CI 0.05 to 0.94) (Aguiar 2021).

Menstrual Pain in Primary Dysmenorrhea

Primary dysmenorrhea (painful menstrual cramps without underlying pelvic disease) is proposed to ease when light improves blood supply to the uterine muscle. Sham-controlled RCTs of skin-adhesive light devices on acupuncture points come from one Pusan National University group co-authoring with device maker Color Seven, a conflict of interest (Shin 2012; Hong 2016). A meta-analysis pooled three sham-controlled RCTs, most with some risk-of-bias concerns, and reported only minor, transient adverse effects.

Magnitude: Pain score 4.02 points lower than sham after 12 weeks (95% CI 0.82 to 7.21) across three RCTs with 150 participants (Ang 2025).

Low 🟩

In dry AMD (age-related macular degeneration), the LumiThera-run LIGHTSITE III trial reported modest acuity gains, sustained at 24 months (Jaffe 2026), and the device received FDA authorization (FDA De Novo DEN230083). The earlier Cochrane review found no meaningful acuity benefit. Net reading: a small, industry-sponsored benefit awaits independent confirmation.

Magnitude: 2.4 letters more than sham at 13 months (95% CI 0.1 to 4.7) (Boyer 2024); no acuity difference in the Cochrane review, mean difference 0.02 logMAR (a standard acuity scale), 95% CI −0.02 to 0.05 (Henein 2021).

Color Vision in Healthy Aging Eyes

Jeffery’s University College London group reports that brief 670 nm exposures improve cone (color) vision in adults over about 40 (Shinhmar 2020), with morning timing effective. Studies are small, non-randomized within-person comparisons, unreplicated by other groups.

Magnitude: Blue–yellow (tritan) color-contrast thresholds 17% lower 3 hours after one morning exposure, within-subject, no control group for this figure; an unexposed cohort showed no change (Shinhmar 2021).

Breast Cancer–Related Lymphedema ⚠️ Conflicted

Lymphedema (arm swelling after breast cancer treatment) has been treated with laser over the armpit and arm. Chiu 2023 found less swelling with specific regimens, whereas Chen 2019 found no significant pooled reduction in arm circumference or volume. Net reading: no reliable swelling benefit is established.

Magnitude: Reduced swelling only in subgroups receiving more than 15 sessions or 1.5–2 J/cm² three times weekly (a meta-analysis, Chiu 2023); pooled arm-volume differences were not significant (Chen 2019); the literature reports no consistent pooled outcome figure.

Allergic Rhinitis Symptoms ⚠️ Conflicted

Light delivered inside the nose is used for allergic rhinitis (hay fever). A meta-analysis found that symptoms improved after treatment but not significantly more than with placebo, pointing to a placebo response. Net reading: no benefit beyond placebo is shown.

Magnitude: Nasal symptoms SMD −0.69 versus placebo, not statistically significant (p-value, the probability of a chance result, 0.167) (Rajai Firouzabadi 2024).

Speculative 🟨

Slower Biological Aging and Longer Lifespan

Daily 670 nm light raised ATP, reduced inflammation, improved mobility, and extended average lifespan in aged fruit flies (Begum 2015). No human lifespan data exist; the basis is animal and mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to alter response. Skin pigmentation, which is genetically determined, absorbs part of red and near-infrared light, so darker skin may deliver a lower dose to deeper tissues at the same device settings.
  • Baseline function: Gains appear larger when function is impaired: color-vision improvement occurred after about age 40, not in younger adults (Shinhmar 2020), and cognitive gains are documented mainly in impairment, though one crossover trial found acute working-memory gains in healthy older adults (Yang 2025).
  • Baseline biomarkers: Thyroid effects were seen in people with autoimmune thyroid antibodies (Höfling 2013), whereas glucose effects were seen in metabolically healthy adults (Powner 2024) and in type 2 diabetes (Scontri 2023); whether baseline glucose changes the size of response is untested.
  • Sex: Hair-density gains occurred in both men and women (a meta-analysis, Liu 2019) and were independent of sex in one trial (Jimenez 2014), and color-vision gains were 17% in both sexes (Shinhmar 2021). No consistent sex difference has been reported elsewhere.
  • Pre-existing conditions: Benefits are documented mainly in specific conditions (knee osteoarthritis, diabetic ulcers, cognitive impairment, cancer therapy). Healthy people have little outcome data, so benefit for them is largely extrapolated.
  • Age: Older adults may gain more because mitochondrial function declines with age; cognitive trials enrolled mostly adults over 60. No trial has tested age-specific dosing.
  • Dose and timing: Response follows a biphasic curve, so more light is not better (a review, Huang 2009); morning but not afternoon exposure improved color vision (Shinhmar 2021).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been shown more often with light than with sham in trials from more than one research group, and meta-analyses report adverse events similar to placebo.

Medium 🟥 🟥

Darker Pigmentation, Most Prominent in Darker Skin

Visible light, including red, is thought to stimulate melanin production. In two randomized dose-escalation trials from one University of California, Davis group, high-dose red LED light caused hyperpigmentation (patchy skin darkening) in about a third of treated participants and none given mock irradiation, more prominently in darker skin; all cases improved or resolved within three months. Separately, visible light (400–700 nm, including blue) produced darker, longer-lasting pigmentation than long-wave ultraviolet light in skin types IV–VI (olive to dark skin) and none in type II (Mahmoud 2010).

Magnitude: Hyperpigmentation in 10 of 30 participants (33.3%) at 320 J/cm² versus 0 of 20 with mock irradiation, and in 11 of 30 (36.7%) at 480 J/cm² versus 0 of 20 (Jagdeo 2020).

Blistering at Very High Doses

Very high doses of red LED light can injure skin, probably through light absorption by melanin. In the same two University of California, Davis trials, a blister ended dose escalation at 480 J/cm² in a Black participant, and blistering or redness lasting over 24 hours ended it at 640 J/cm² in two non-Hispanic white participants; the temperature-matched mock device caused no blisters. Reactions were mild and resolved, and darker skin tolerated lower doses.

Magnitude: Redness lasting over 24 hours in 5 of 30 participants (16.7%) at 480 J/cm² versus 0 of 20 with mock irradiation; dose-limiting blistering or prolonged redness in 1 participant at 480 J/cm² and 2 at 640 J/cm², none in the mock groups (Jagdeo 2020).

Low 🟥

Retinal Injury From Direct Eye Exposure ⚠️ Conflicted

A 12-year-old developed central-retina damage after five months of red-laser nearsightedness treatment (Liu 2023); an adult with dry macular degeneration lost central retinal tissue weeks after photobiomodulation (Battaglia Parodi 2025). A 70-child RCT found no retinal toxicity over 9 months. Net reading: rare retinal injury is plausible with retina-directed light.

Magnitude: Not quantified in available studies. Injury is documented only in isolated case reports, and the controlled trial found no retinal abnormalities to count (Jiang 2025).

Acute Angle-Closure Glaucoma With Face Masks

A healthy 43-year-old developed sudden angle-closure glaucoma (blocked eye drainage that sharply raises eye pressure) in both eyes after two weeks of red-light face-mask use, attributed to fluid accumulating behind the iris. Vision recovered fully after stopping the mask and treatment. This single case report cannot establish causation.

Magnitude: Not quantified in available studies. Only one case report exists, so no rate or comparison group is available (Labkovich 2026).

Brain Artery Clot After Recent Stroke

A 69-year-old recovering from stroke after vertebral artery dissection (a tear in a neck artery) became comatose from basilar artery thrombosis (a clot in the brain’s main rear artery) after a transcranial helmet session. The authors judged causation likely from timing. A single case cannot confirm it.

Magnitude: Not quantified in available studies. Only one case report exists, so no rate or comparison group is available (van Rooij 2025).

Mild Transient Local Effects ⚠️ Conflicted

Users report warmth, tingling, mild redness, headache, or glare. A meta-analysis of neck-pain trials found side effects mild and no more frequent than with placebo (Chow 2009). Net reading: such effects are not clearly attributable to the light itself.

Magnitude: Adverse events in 4 of 10 active versus 6 of 10 sham users of home transcranial devices, none serious (Rashidi-Ranjbar 2026).

Speculative 🟨

Seizures From Flickering Devices

Some brain devices pulse light at 10–40 Hz. Flickering light can trigger photosensitive epilepsy (seizures provoked by flashing light); no case linked to these devices is published. The basis is mechanistic only.

Low Blood Sugar in Glucose-Lowering Drug Users

Light lowered glucose in healthy adults (Powner 2024) and in type 2 diabetes (Scontri 2023), so additive lowering with insulin or glipizide is conceivable. Basis is inferred; no hypoglycemia (dangerously low blood sugar) is reported.

Thyroid Over-Replacement in Levothyroxine Users

Neck irradiation lowered levothyroxine needs in autoimmune hypothyroidism (Höfling 2013), so unchanged doses could cause over-replacement (excess hormone causing palpitations or bone loss). No case is reported; the basis is inferred only.

Stimulation of Existing Tumors ⚠️ Conflicted

A systematic review found mixed cancer-cell results and tumor growth in two animal models (Bensadoun 2020). A 94-patient cancer RCT found longer survival without progression with light (Antunes 2017). Net reading: no harm in patients.

Risk-Modifying Factors

  • Genetic polymorphisms: No drug-metabolism variant applies. Inherited porphyrias such as erythropoietic protoporphyria (porphyrin buildup causing light-triggered skin pain) raise sensitivity to visible light; reactions to red-only devices are not documented.
  • Baseline biomarkers: In levothyroxine users, a TSH (thyroid-stimulating hormone) already near the low end of normal leaves little margin before over-replacement if neck exposure lowers hormone needs (Höfling 2013).
  • Sex: No sex difference in adverse effects has been reported. Pregnant women are excluded from nearly all trials, so the safety of abdominal or pelvic exposure in pregnancy is unknown.
  • Pre-existing conditions: Retinal disease, malignancy in the treatment field, photosensitivity disorders, recent stroke (for transcranial devices), and photosensitive epilepsy (for flickering devices) raise documented or theoretical risk. Skin types IV–VI carry higher pigmentation risk (Mahmoud 2010).
  • Age: Children appear vulnerable to retinal injury from retina-directed lasers (Liu 2023). Older adults more often take photosensitizing drugs (medicines that heighten skin reactions to light) and have reduced heat sensation, which may raise the risk of unnoticed overheating from high-power panels.

Key Interactions & Contraindications

Documented interactions:

  • Porfimer (Photofrin): Activated by 630 nm red laser light; the label requires avoiding sunlight and bright indoor light for at least 30 days after injection (Photofrin label). Red-light sessions in this window risk severe phototoxic (light-triggered chemical) burns. Avoid for at least 30 days.
  • Verteporfin (Visudyne): Activated at 689 nm; the label requires avoiding direct sunlight and bright indoor light for 5 days after infusion (Visudyne label). Red or near-infrared sessions in this window risk skin and eye phototoxicity. Avoid for 5 days.
  • Aminolevulinic acid (Ameluz) photodynamic therapy (drug-plus-light treatment that destroys targeted tissue): The gel creates a red-light-activated photosensitizer; the label requires shielding treated skin from sunlight for 48 hours (Ameluz label). Panel exposure over treated areas risks blistering burns. Avoid treated areas for 48 hours.
  • Levothyroxine: Neck irradiation lowered levothyroxine requirements in autoimmune hypothyroidism (Höfling 2013), so unchanged doses could cause over-replacement. TSH recheck 6–8 weeks after starting regular neck exposure.
  • Chemoradiation for head and neck cancer: No adverse interaction found: intraoral light during cisplatin-based chemoradiation did not worsen tumor response or survival in an RCT (Antunes 2017).
  • Oral glucose-lowering drugs (metformin, glipizide, glimepiride): In type 2 diabetes, 830 nm light lowered glucose without medication; with these drugs, only the glucose-curve area fell more than with sham (Scontri 2023). Consequence: possible additive lowering and hypoglycemia. Early glucose checks detect it.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Systemic photosensitizing drugs (doxycycline, ciprofloxacin, hydrochlorothiazide, amiodarone, chlorpromazine, isotretinoin, over-the-counter naproxen): Inferred from additive photosensitization; most act mainly in the ultraviolet range, so red-light reactions are unlikely but untested. Consequence: exaggerated redness or burning. A short test session on a small area limits exposure.
  • Methylene blue: Inferred from its strong absorption near 660 nm, the basis of methylene-blue photodynamic therapy; combined with red light it could generate tissue-damaging oxygen radicals. Consequence: phototoxic skin or eye injury. Separating supplement use from red-light sessions limits overlap.
  • St John’s wort (Hypericum perforatum): Inferred from hypericin (a photosensitizer absorbing orange-red light near 590 nm); regular use could heighten skin reactions to red light. Consequence: phototoxic redness. Shorter initial sessions reveal sensitivity.
  • Insulin and glucose-lowering supplements (berberine): Inferred from additive glucose lowering (Powner 2024); no human study combined them with light. Consequence: lower post-meal glucose and, theoretically, hypoglycemia. Glucose checks during the first weeks of regular sessions detect it.
  • Other light and heat interventions (infrared sauna, heat lamps, additional light devices): Inferred from the biphasic dose response described in a review (Huang 2009) and added heat; stacking may cancel benefit or raise burn risk. Counting total exposure across devices limits overdosing.

Populations who should avoid Low-Level Light Therapy:

  • People within 30 days of porfimer injection, 5 days of verteporfin infusion, or 48 hours of aminolevulinic acid photodynamic therapy (treated areas), per the Photofrin label, Visudyne label, and Ameluz label.
  • Children using retina-directed red-laser devices outside supervised eye care, based on documented retinal injury (Liu 2023).
  • People recovering from recent stroke or arterial dissection, for transcranial devices, based on one case report of basilar artery thrombosis after a helmet session (van Rooij 2025).
  • People with photosensitive epilepsy using flickering (10–40 Hz pulsed) devices; inferred from flicker-triggered seizures, no human data with these devices.
  • People with known or suspected malignancy in the treatment field outside oncology-supervised protocols; inferred from laboratory and animal tumor-growth signals summarized in a systematic review (Bensadoun 2020), although human data are reassuring.
  • Pregnant women, for abdominal or pelvic exposure; inferred from near-infrared light penetrating several centimeters into tissue and so reaching the uterus and fetus, no human data.
  • People with cutaneous porphyrias; inferred from porphyrin absorption of visible light, no human data with red-light devices.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Eye protection: Opaque goggles rated for the device’s wavelengths are used with lasers and high-intensity panels, and emitters are never viewed directly; this prevents retinal injury (Liu 2023).
  • Low-intensity eye protocols: Eye-directed protocols in healthy adults use about 8 mW/cm² (milliwatts per square centimeter, light intensity) for 3 minutes (Shinhmar 2021), limiting retinal light dose; any blurred vision or lasting afterimage is a stop signal.
  • Medication review: Checking for porfimer, verteporfin, aminolevulinic acid, and systemic photosensitizers before each new course prevents phototoxic burns; label windows are 30 days, 5 days, and 48 hours respectively.
  • Test patch for darker skin: A short first session on a small area, with checks for darkening over two weeks, limits pigmentation risk in skin types IV–VI (Mahmoud 2010).
  • Thyroid monitoring: Levothyroxine users exposing the neck recheck TSH 6–8 weeks after starting; a TSH below the reference range prompts dose review, preventing over-replacement.
  • Heat check: Panels are kept at the manufacturer’s stated distance and sessions stop if skin feels hot; this prevents burns, especially in people with reduced heat sensation.
  • Tumor sites: Known or suspected cancers are not irradiated outside oncology protocols, limiting theoretical tumor stimulation (a systematic review, Bensadoun 2020).
  • Non-flicker mode: Continuous rather than pulsed settings are used by people with seizure history or flicker-triggered migraine, removing the flicker trigger.
  • Moderate dosing: Sessions stay within studied doses, below the per-session doses at which blistering began (480 J/cm² in darker skin, 640 J/cm² in lighter skin) (Jagdeo 2020) and the inhibitory arm of the biphasic curve (a review, Huang 2009).

Therapeutic Protocol

Other parameters without a citation (timing, frequency, distance, session length, course duration) reflect common practice.

  • Competing approaches: Clinic lasers deliver high, localized doses for specific conditions; home LED panels deliver lower, diffuse doses for general wellness. Most trials tested clinic or condition-specific devices, so evidence for whole-body home panels is extrapolated.
  • Joint and tendon pain: 4–8 J per point at 785–860 nm, or 1–3 J at 904 nm: World Association for Laser Therapy doses (whose members deliver the therapy) pooled by Stausholm 2019; typically 2–3 sessions weekly for 2–8 weeks.
  • Hair loss: A 655 nm laser comb three times weekly for 26 weeks (Jimenez 2014); FDA-cleared caps and helmets use similar schedules, per a systematic review (Lueangarun 2021).
  • Aging vision: 3 minutes of 670 nm light at about 8 mW/cm² into the open eye between 8 and 9 AM (Shinhmar 2021); popularized by Andrew Huberman (Huberman Lab podcast).
  • Dry macular degeneration: 590, 660, and 850 nm in nine sessions over 3–5 weeks, repeated every 4 months (Boyer 2024).
  • Cognition: 808–810 nm near-infrared over the forehead or default-mode network sites (brain hubs active at rest), about 20 minutes, six days weekly for 6–12 weeks (Chun 2026; Rashidi-Ranjbar 2026).
  • Exercise: 20–60 J per small muscle group or 60–300 J per large group at 655–950 nm before exercise (a systematic review, Vanin 2018); popularized by Leal-Junior’s laboratory.
  • Glucose (research only): 15 minutes of 670 nm light to the back, 45 minutes before a glucose load (Powner 2024).
  • Home panels: The one large-area panel trial used 611–650 nm light at about 9 J/cm² twice weekly for 30 sessions (Wunsch 2014); whole-body red and near-infrared panel schedules have no outcome trials.
  • Time of day: Morning for vision (Shinhmar 2021); before training for performance (a systematic review, Vanin 2018); evening red light was studied for sleep (Zhao 2012).
  • Duration of effect: A single morning 670 nm exposure improved color vision for up to a week (Shinhmar 2021), so effects outlast sessions; the half-life concept for drugs does not apply.
  • Single versus split sessions: Trials deliver one session per day; splitting a daily dose into several shorter sessions has not been studied.
  • Genetic polymorphisms: No genetic test guides dosing. Deeper targets in darker skin may receive less light; no trial has tested dose adjustment by skin type.
  • Sex: Hair-density gains were independent of sex (Jimenez 2014), and color-vision responses were similar in men and women (Shinhmar 2021); no sex-specific protocol exists.
  • Age: Color-vision benefit appeared only after about age 40 (Shinhmar 2020); cognitive trials enrolled older adults with impairment. No age-based dose changes are established.
  • Baseline biomarkers: Lower baseline function (cognition, color contrast, existing pain) predicts larger measurable change; thyroid status (TSH) matters before regular neck exposure.
  • Pre-existing conditions: Trials in mucositis, ulcers, and macular degeneration used condition-specific protocols that differ substantially from generic panel use; results apply to the tested protocol.

Discontinuation & Cycling

  • Lifelong or short-term: Knee-pain relief persisted at follow-ups 1–12 weeks after therapy (a meta-analysis, Stausholm 2019), and macular-degeneration protocols repeat every 4 months (Boyer 2024). Longer persistence is unmeasured, so use is typically ongoing or repeated in courses.
  • Withdrawal effects: No withdrawal syndrome is known. Hair gained with light is expected to regress after stopping, as with other hair-loss treatments, but no trial has measured this.
  • Tapering: Not required; sessions can stop abruptly. Levothyroxine users who stop regular neck exposure recheck TSH, since hormone needs may rise again.
  • Cycling: Macular-degeneration protocols cycle treatment series every 4 months (Boyer 2024); for other uses cycling is untested, and the biphasic dose response (a review, Huang 2009) favors moderate, spaced sessions over escalating daily exposure.

Sourcing and Quality

  • Wavelength accuracy: Trials used specific peaks (630–670 nm red; 780–860 nm near-infrared). Devices listing exact peaks with independent spectrometer data are preferable to vague “full-spectrum” claims.
  • Irradiance claims: Consumer power figures are often measured at contact or with inaccurate meters, and ConsumerLab reported false claims by one panel maker (ConsumerLab review). Independent irradiance testing at the stated distance matters more than the advertised wattage.
  • Regulatory status: FDA clearance covers specific uses, such as hair-growth caps, as a systematic review documents (Lueangarun 2021); Valeda is authorized for dry macular degeneration (FDA De Novo DEN230083). FDA registration does not denote approval or clearance (21 CFR 807.39).
  • Laser versus LED: Lasers deliver concentrated, localized doses and require eye protection; LEDs cover wide areas at lower intensity. Clinic lasers suit joints and tendons; LED panels suit skin and broad exposure.
  • Reputable makers: Clinic: Multi Radiance Medical, Erchonia, THOR; brain: Vielight; eye: LumiThera, acquired by Alcon in 2025 (NCT06351605); hair: HairMax; home panels: Joovv, Mito Red Light. Several fund research, a conflict of interest.
  • Flicker and electromagnetic fields: Low-flicker drivers matter for flicker-sensitive users; electromagnetic-field claims are marketing differentiators without outcome data.

Practical Considerations

  • Time to effect: Color vision changed within 3 hours (Shinhmar 2021); pain relief appears over 2–8-week courses; cognitive gains were measured after 6–12 weeks; hair density after 16–26 weeks (Jimenez 2014).
  • Common pitfalls: Typical mistakes are treating through clothing, using the wrong distance, assuming more time is better despite the biphasic curve, unprotected eyes, irregular sessions, and expecting home panels to reproduce clinic-laser trial results.
  • Regulatory status: Devices are regulated for specific claims; Medicare’s national coverage determination excludes infrared therapy devices for neuropathy, wounds, and ulcers (CMS NCD 270.6), so most use is self-funded.
  • Cost and payer incentives: Home panels range from a few hundred to several thousand US dollars. Because payers rarely reimburse light therapy, they have little incentive to fund trials, leaving device makers as the main funders, a structural bias in the evidence.

Interaction with Foundational Habits

  • Sleep: Indirect, potentially supportive. Red light only weakly activates the eye’s melatonin-suppressing receptors, so evening red light is less disruptive than white light. In 20 athletes, 30 minutes of nightly whole-body red light for 14 days improved Pittsburgh Sleep Quality Index scores and melatonin (Zhao 2012).
  • Nutrition: No direct diet interaction is known. Light before a glucose load blunted the post-meal rise (Powner 2024), so timing sessions before carbohydrate-rich meals is a hypothesis. Photosensitizing supplements (St John’s wort, methylene blue) are the main dietary consideration.
  • Exercise: Potentiating in pooled trials: pre-exercise light modestly improved repetitions and time to exhaustion (Vanin 2018), though small independent trials found no effect (Flores 2023). No evidence suggests it blunts training adaptations.
  • Stress management: Indirect. Light therapy reduced depressive symptoms (a meta-analysis, Seok 2026) but did not change anxiety scores in a cognitive-impairment trial (de Oliveira 2024); no cortisol data exist.

Monitoring Protocol & Defining Success

Baseline testing before a first course records the function the light is meant to change and screens the few safety concerns. A medication review identifies light-activated drugs, photosensitizers, and levothyroxine. Levothyroxine users planning neck exposure obtain a TSH; people using eye-directed light obtain a visual acuity measurement and retinal examination; those targeting glucose obtain a fasting glucose or continuous glucose monitor trace; cognitive and pain goals use a standardized score.

Ongoing monitoring follows the course: at 4 weeks, at the end of the first 8–12-week course, then every 6–12 months during continued use. TSH is rechecked 6–8 weeks after regular neck exposure begins, and visual acuity is rechecked at any change in vision. Success means a measurable gain in the targeted outcome without new symptoms.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
TSH 0.4–4.0 mIU/L (standard reference range) Safety check: over-replacement if neck light lowers hormone needs Levothyroxine users exposing the neck (Höfling 2013); morning draw before the daily dose; pair with free T4 (thyroxine)
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change; safety check in insulin users Fasting 8 or more hours; a CGM (continuous glucose monitor) captures post-meal effects better (Powner 2024)
BCVA No established target; track change from own baseline Safety check for retinal injury; expected to change in macular degeneration BCVA (best-corrected visual acuity, sharpest vision with glasses); letter gains measured in Boyer 2024; any drop is a stop signal for eye-directed use
MoCA score No established target; track change from own baseline Expected to change with transcranial use MoCA (Montreal Cognitive Assessment, a 30-point cognitive screen) used in Chun 2026; alternate versions limit practice effects
Pain VAS No established target; track change from own baseline Expected to change with joint or tendon use 0–100 mm scale as in Stausholm 2019; record at the same time of day
Terminal hair density No established target; track change from own baseline Expected to change with scalp use Standardized photographs of the same scalp area, as in Jimenez 2014

Qualitative markers:

  • Pain and stiffness during daily activities
  • Sleep quality and ease of falling asleep
  • Daytime energy and mood
  • Color and contrast perception in dim light
  • Skin texture and fine lines
  • Eye comfort, afterimages, or headaches after sessions (safety signals)

Emerging Research

  • NirsCure-03A home near-infrared trial: Phase 3, 320 people with mild-to-moderate Alzheimer’s disease, 52 weeks of sham-controlled home use; primary endpoint ADAS-Cog13 (a cognitive scale); recruiting, completion 2027 (NCT07262645). A positive result would strengthen the cognition item; a null result would weaken it. Sponsor is the device maker.
  • TRAP-AD dose-finding trial: Phase 2, 196 adults with amnestic (memory-predominant) mild cognitive impairment or early Alzheimer’s, 8 weeks of 808 nm versus sham; endpoint RBANS (a neuropsychological battery). Completed February 2026, no results posted (NCT04784416). Positive results would support dose-dependent benefit; null results would weaken the cognition item.
  • Vielight Neuro RX Gamma pivotal trial: 228 people with moderate-to-severe Alzheimer’s; suspended, completion date (May 2023) passed, no results posted (NCT03484143). Publication of positive results would broaden the cognition item to advanced disease; null results would narrow it.
  • GLOBALIGHT registry: 500-person real-world registry of the Valeda device in dry macular degeneration, run by LumiThera, completion 2028 (NCT06351605). Sustained acuity gains would strengthen the macular-degeneration item; fading benefit or new safety signals would weaken it.
  • Hard-to-heal ulcers in frail older adults: Umeå non-randomized home-care study, 1,290 enrolled, completion 2027 (NCT07520825). Its arterial-ulcer report found median healing in 135 days with light versus 252 after revascularization (Degerman 2025). Positive results would extend wound evidence to frail older adults; null results would temper it.
  • Light plus supplement for cognition: 180-person trial combining light with a nutritional supplement to raise brain energy; not yet recruiting, completion 2030 (NCT07793604). A positive result would add healthy-adult cognitive data; a null result would weaken extrapolation to healthy users.
  • Long-term macular data: The 24-month LIGHTSITE III analysis reported a 6.2-letter gain and less progression to geographic atrophy (advanced dry macular degeneration) (Jaffe 2026); independent replication would decide whether the item moves above Low.
  • Open questions: Key gaps are outcome trials of whole-body home panels in healthy adults, long-term retinal safety of eye-directed light (Liu 2023; Jiang 2025), longer-term glucose trials (Powner 2024; Scontri 2023), and independent replication of color-vision findings (Shinhmar 2021). The umbrella review rated most outcomes low certainty (Son 2025).
  • Mechanism debate: Whether cytochrome c oxidase or nitric oxide release drives the effect (Quirk 2020) affects which wavelengths and doses work best; resolving it could strengthen or weaken protocol choices.

Conclusion

Low-level light therapy uses weak red and near-infrared light to nudge how cells produce energy and handle stress. For health-focused adults, its appeal is that it is drug-free, low-risk, and increasingly available at home.

The strongest evidence concerns specific problems rather than general aging. Several independent groups have shown reductions in joint, tendon, and nerve pain, better memory and thinking scores in people with early cognitive decline, faster healing of diabetic foot ulcers, fewer mouth sores during cancer treatment, regrowth in pattern hair loss, and modest muscle-endurance gains. Support is thinner for mood, skin texture, immune-driven thyroid disease, and post-meal blood sugar, and weaker still for vision in age-related central vision loss and for color vision in healthy older eyes. Claims of slower aging or longer life rest on fly studies alone.

The harms recorded so far are rare or dose-related: eye injury with lasers aimed into the eye or masks worn over it, skin darkening and blistering at high doses, mostly in darker skin, and dangerous reactions with light-activated cancer and eye drugs. Fears that light feeds tumors have not been borne out in patients.

The evidence base is large but uneven, built mostly from small trials with varied devices and doses, and much of it is funded or run by device makers, which is a conflict of interest. Results from clinic devices and specific conditions do not automatically carry over to whole-body home panels used by healthy people, so for that use the benefits remain largely uncertain.

Top - Benefits - Risks - Protocol